Debby den Uyl

Summary

Affiliation: VU University Medical Center
Country: The Netherlands

Publications

  1. ncbi Glucocorticoid-induced osteoporosis
    D den Uyl
    VU University Medical Center, Department of Rheumatology, 1081 HV Amsterdam, The Netherlands
    Clin Exp Rheumatol 29:S93-8. 2011
  2. ncbi Advances in glucocorticoid-induced osteoporosis
    Debby den Uyl
    Department of Rheumatology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    Curr Rheumatol Rep 13:233-40. 2011
  3. ncbi (Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosis
    Debby den Uyl
    Department of Rheumatology, VU Medical Centre, De Boelelaan 1117, 1081 NV Amsterdam, The Netherlands
    Arthritis Res Ther 13:R5. 2011
  4. ncbi Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction
    Debby den Uyl
    VU University Medical Center, Amsterdam, The Netherlands
    Arthritis Rheum 64:639-46. 2012
  5. ncbi Patient preference and acceptability of calcium plus vitamin D3 supplementation: a randomised, open, cross-over trial
    Debby den Uyl
    Department of Rheumatology, VU Medical Centre, Room 3A58, P O Box 7057, 1007 MB, Amsterdam, The Netherlands
    Clin Rheumatol 29:465-72. 2010
  6. ncbi Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with
    Sue Ellen Verbrugge
    Department of Rheumatology, VU Institute for Cancer and Immunology, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    J Pharmacol Exp Ther 341:174-82. 2012

Collaborators

Detail Information

Publications6

  1. ncbi Glucocorticoid-induced osteoporosis
    D den Uyl
    VU University Medical Center, Department of Rheumatology, 1081 HV Amsterdam, The Netherlands
    Clin Exp Rheumatol 29:S93-8. 2011
    ..Different treatment options are summarised considering the pathogenesis of glucocorticoid-induced osteoporosis. Improved insights into pathogenesis might result in development of new treatment possibilities...
  2. ncbi Advances in glucocorticoid-induced osteoporosis
    Debby den Uyl
    Department of Rheumatology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    Curr Rheumatol Rep 13:233-40. 2011
    ....
  3. ncbi (Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosis
    Debby den Uyl
    Department of Rheumatology, VU Medical Centre, De Boelelaan 1117, 1081 NV Amsterdam, The Netherlands
    Arthritis Res Ther 13:R5. 2011
    ..The co-occurrence of cardiovascular disease and osteoporosis prompted us to review the evidence of an association between cardiovascular (CV) disease and osteoporosis and potential shared common pathophysiological mechanisms...
  4. ncbi Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction
    Debby den Uyl
    VU University Medical Center, Amsterdam, The Netherlands
    Arthritis Rheum 64:639-46. 2012
    ..To investigate the dose-related effects of glucocorticoid treatment on glucose tolerance, beta cell function, and insulin sensitivity in patients with early active rheumatoid arthritis (RA)...
  5. ncbi Patient preference and acceptability of calcium plus vitamin D3 supplementation: a randomised, open, cross-over trial
    Debby den Uyl
    Department of Rheumatology, VU Medical Centre, Room 3A58, P O Box 7057, 1007 MB, Amsterdam, The Netherlands
    Clin Rheumatol 29:465-72. 2010
    ..A significant greater number of patients considered the chewable tablet as preferable and acceptable to the sachet, containing calcium and vitamin D(3). TRIAL REGISTRATION: Current Controlled Trials ISRCTN18822358...
  6. ncbi Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with
    Sue Ellen Verbrugge
    Department of Rheumatology, VU Institute for Cancer and Immunology, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    J Pharmacol Exp Ther 341:174-82. 2012
    ..These results indicate that the pharmacologic activity of these PIs may be hindered by drug resistance mechanisms involving PSMB5 mutations and PI extrusion via Pgp...